Cord Blood News Volume 10.25 | Jun 28 2018

TOP STORY

Early Gestational Mesenchymal Stem Cell Secretome Attenuates Experimental Bronchopulmonary Dysplasia in Part via Exosome-Associated Factor TSG-6

Using a neonatal mouse model of human bronchopulmonary dysplasia, scientists evaluated the therapeutic efficiency of early gestational age human umbilical cord-derived MSC exosomes fraction and its exosomal factor, tumor necrosis factor alpha-stimulated gene-6 (TSG-6). [Stem Cell Res Ther] Full Article

(Ranked by impact factor of the journal)

Human Mesenchymal‐Stem‐Cells‐Derived Exosomes Are Important in Enhancing Porcine Islet Resistance to Hypoxia

The authors investigated whether exosomes from human umbilical cord‐derived MSC‐conditioned medium could increase the survival and function of neonatal porcine islet cell clusters exposed to hypoxia. [Xenotransplantation] Abstract

Ikaros Family Zinc-Finger 1 Mutation Is an Independent Factor for the Poor Prognosis of Adult B-Cell Acute Lymphoblastic Leukemia, and Allogeneic Hematopoietic Stem Cell Transplantation Can Improve Clinical Outcomes

To investigate the prognosis of patients with adult B-cell acute lymphoblastic leukemia (B-ALL) with Ikaros family zinc-finger 1 (IKZF1) mutation and determine the role of allogeneic hematopoietic stem cell transplantation in improving the clinical outcome, researchers detected the IKZF1 mutation and BCR-ABL fusion gene at diagnosis in the bone marrow of 164 adult patients with B-ALL, and analyzed the clinical data of these patients retrospectively. [Bone Marrow Transplant] Abstract

Corneal Endothelial Regeneration Using Mesenchymal Stem Cell Derived from Human Umbilical Cord

After inducing differentiation with medium containing glycogen synthase kinase 3-β inhibitor, umbilical cord-MSCs formed polygonal corneal endothelial-like cells which functioned as tissue-engineered corneal endothelium. [Stem Cells Dev] Abstract

Efficacy and Safety of a Clinically Relevant Foamy Vector Design in Human Hematopoietic Repopulating Cells

Scientists developed and analyzed the efficacy and safety of a high‐titer, clinically relevant foamy viral (FV) vector driven by the housekeeping promoter elongation factor‐1α and insulated with an enhancer blocking A1 insulator (FV‐EGW‐A1). Human CD34⁺ cord blood cells were exposed to an enhanced green fluorescent protein expressing vector, FV‐EGW‐A1, at a multiplicity of infection of ten and then maintained in vitro or transplanted into immunodeficient mice. [J Gene Med] Abstract

Epigenetic Changes in Umbilical Cord Mesenchymal Stromal Cells upon Stimulation and Culture Expansion

Fourteen days after culture expansion, umbilical cord-derived MSCs displayed minor phenotypical and functional changes but showed >4000 significantly differentially methylated sites, mostly concerning genes involved in membrane composition, cell adhesion and transmembrane signaling. [Cytotherapy] Abstract

Subscribe to one of our other 19 science newsletters such as Hematopoiesis News & Cell Therapy News.

Hematopoietic Stem Cell Therapy for Autoimmune Diseases – Clinical Experience and Mechanisms

The authors discuss the current role and future perspectives of hematopoietic stem cell transplantation in autoimmune diseases, focusing on recent published clinical and scientific studies and recommendations in the field. [J Autoimmun] Abstract | Graphical Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

Cellenkos, Inc. Announces Neuroinflammation Research Collaboration with The University of Texas Health Science Center at Houston

Cellenkos^™ and The University Of Texas Health Science Center at Houston announced a research collaboration for application of cord blood-derived regulatory T cells as adoptive therapy for treatment of neuroinflammatory disorders. [Cellenkos^™ (PR Newswire Association LLC.)] Press Release

Incyte Announces REACH1 Pivotal Trial Meets Primary Endpoint of Overall Response Rate for Ruxolitinib (Jakafi^®) in Steroid-Refractory Acute Graft-versus-Host Disease

Incyte Corporation announced positive topline results from its ongoing pivotal Phase II REACH1 trial evaluating ruxolitinib in combination with corticosteroids for the treatment of patients with steroid-refractory acute graft versus host disease. [Incyte Corporation] Press Release

Final Patient Receives Treatment in ExCellThera Stem Cell Clinical Trial for Severe Blood Cancers

ExCellThera Inc. announced the close of its initial, 25-patient clinical trial for its lead technology, ECT-001. ECT-001 was used in this Phase I/II multicentre trial to expand blood stem cells from the umbilical cord, which have been shown to be better tolerated by the patient than stem cells from a family member or unrelated donor. [ExCellThera Inc.] Press Release

Kalytera Provides Update on Its Lead Program in Prevention and Treatment of GvHD

Kalytera Therapeutics, Inc. provided an update on its lead clinical development program evaluating cannabidiol for the prevention and treatment of acute graft versus host disease (GvHD). [Kalytera Therapeutics, Inc.] Press Release

MaaT Pharma and Lutech Sign Licensing Agreement on Microbiome Therapy for Graft-vs-Host Disease

MaaT Pharma announced a licensing agreement under which MaaT Pharma will receive world-wide exclusive rights for the therapeutic application of allogeneic Fecal Microbiome Transplants to treat acute graft versus host disease in patients following stem cell transplantation. [MaaT Pharma] Press Release

Science Candidates: High-Tech Smarts Aren’t Enough for Defeated Obama Aide

For many first-time congressional candidates with science and technology backgrounds, fundraising can be a major obstacle. Not to Brian Forde, who was once a senior technology adviser to former-President Barack Obama. [ScienceInsider] Editorial

Firm That Tallies Controversial Journal Impact Scores Moves to Provide More Context

Stung by years of criticism that its journal impact factors have distorted scholarly publishing, the private firm Clarivate Analytics based in Philadelphia, Pennsylvania, rolled out an updated version of its Journal Citation Reports database that it says provides context useful to understanding journals’ characteristics and audiences. [ScienceInsider] Editorial

Macchiarini Guilty of Misconduct, but Whistleblowers Share Blame, New Karolinska Institute Verdict Finds

The Karolinska Institute in Stockholm has finally, officially, found disgraced surgeon Paolo Macchiarini guilty of scientific misconduct. However, the verdict is a bitter pill for the four people who raised the alarm about Macchiarini’s fraud. [ScienceInsider] Editorial

Worrying Changes in Hungary

The European country’s autocratic government has made a disturbing grab at the nation’s scientific institutions. [Nature News] Editorial

Senate Panel Proposes $2 Billion, 5.4% Increase for NIH

A U.S. Senate appropriations subcommittee approved a spending bill that calls for giving the National Institutes of Health (NIH) a $2 billion, 5.4% increase to $39.1 billion in the 2019 fiscal year that begins 1 October. [ScienceInsider] Editorial

NEW 2018 Till & McCulloch Meetings (TMM2018)
November 12-14, 2018
Ottawa, Ontario, Canada

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Associate – Cancer Biology (Trustees of Boston University Medical Campus)

Postdoctoral Fellow Positions – Hematopoietic Stem Cell Biology (Nationwide Children’s Hospital)

Research Fellow – Epigenetics and Hematology (University of Edinburgh)

PhD Student – Cellular Immunotherapy (Glycostem Therapeutics)

Research Associate – Advanced Cell Culture Biology (The University of Manchester)

Postdoctoral Fellowship – Myeloid Tumors (St. Jude Children’s Research Hospital)

Postdoctoral Positions – Cell Biology (Children’s Hospital of Philadelphia)

Assistant, Associate, or Full Member Faculty – Myeloid Malignancies (Fred Hutchinson Cancer Research Center)

Postdoctoral Position – 3D Chromatin Architecture, Epigenetics and Metabolism (Josep Carreras Leukaemia Research Institute)

Postdoctoral Research Scholar – Hematologic Malignancies (Washington University School of Medicine)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here.